CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. The rise in R&D spending
4.1.2. Increase in pharmaceutical and biotechnology industries
4.2. Market Restraints & Challenges
4.2.1. The rise in implementation imaging cost
4.2.2. The high cost of clinical trials
4.3. Market Opportunities
4.3.1. Emerging economies
4.3.2. Developments of innovative multimodality imaging technology
CHAPTER 5 GLOBAL CLINICAL TRIAL IMAGING MARKET– BY PRODUCTS &
SERVICES
5.1. Introduction
5.2. Services
5.2.1. Operational Imaging Services
5.2.2. Read Analysis Services
5.2.3. System and Technical Support Services
5.2.4. Trial Design Consulting Services
5.3. Software
CHAPTER 6 GLOBAL CLINICAL TRIAL IMAGING MARKET– BY MODALITY
6.1. Introduction
6.2. Computed Tomography
6.3. Magnetic Resonance Imaging
6.4. Ultrasound
6.5. Positron Emission Tomography
6.6. X-Ray
6.7. Echocardiography
6.8. Other Modalities
CHAPTER 7 GLOBAL CLINICAL TRIAL IMAGING MARKET– BY END USER
7.1. Introduction
7.2. Pharmaceutical Companies
7.3. Biotechnology Companies
7.4. Medical Device Manufacturers
7.5. Contract Research Organizations
7.6. Academic and Government Research Institutes
7.7. Other End Users
CHAPTER 8 GLOBAL CLINICAL TRIAL IMAGING MARKET- BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9 GLOBAL CLINICAL TRIAL IMAGING MARKET- COMPANY
PROFILES
9.1. Introduction
9.2. Bioclinica, Inc.
9.3. Parexel International Corporation
9.4. Icon PLC
9.5. Biomedical Systems Corporation
9.6. Biotelemetry, Inc.
9.7. Cardiovascular Imaging Technologies, LLC
9.8. Intrinsic Imaging LLC
9.9. Ixico PLC
9.10. Radiant Sage LLC
9.11. Worldcare Clinical, LLC
9.12. VirtualScopic
9.13. Prism Clinical Imaging
CHAPTER 10 GLOBAL CLINICAL TRIAL IMAGING MARKET- COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11 MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12 APPENDIX
12.1. List of Tables
12.2. List of Figures
